

# 1 A new method using rapid Nanopore metagenomic cell-free DNA sequencing to diagnose 2 bloodstream infections: a prospective observational study

3  
4 Morten Eneberg Nielsen<sup>1</sup>, Kirstine Kobberøe Sjøgaard<sup>2,3</sup>, Søren Michael Karst<sup>1</sup>, Anne Lund Krarup<sup>3,4</sup>,  
5 Hans Linde Nielsen<sup>2,3</sup>, Mads Albertsen<sup>1\*</sup>

6  
7 <sup>1</sup>Aalborg University, Center for Microbial Communities, Dept. of Chemistry and Bioscience, Aalborg, Denmark

8 <sup>2</sup>Aalborg University Hospital, Dept. of Clinical Microbiology, Aalborg, Denmark

9 <sup>3</sup>Aalborg University, Dept. of Clinical Medicine, Aalborg, Denmark

10 <sup>4</sup>Aalborg University Hospital, Dept. of Emergency Medicine, Aalborg, Denmark

11  
12 \*Correspondence: ma@bio.aau.dk

## 13 Abstract

### 14 *Background*

15 Bloodstream infections (BSIs) remain a major cause of mortality, in part due to many patients  
16 developing sepsis or septic shock. To survive sepsis, it is paramount that effective antimicrobial  
17 therapy is initiated rapidly to avoid excess mortality, but the current gold-standard to identify the  
18 pathogen in BSIs, blood culturing, has great limitations with a long turnaround time and a poor  
19 sensitivity. This delay to correct empiric broad-spectrum antimicrobial treatments leads to excess  
20 mortality and antimicrobial resistance development.

### 21 *Methods*

22 In this study we developed a metagenomic next-generation sequencing (mNGS) assay utilizing the  
23 Oxford Nanopore Technologies platform to sequence microbial cell-free DNA from blood plasma. The  
24 method was evaluated in a prospective observational clinical study (n=40) in an emergency ward  
25 setting, where a study sample was taken from the same venipuncture as a blood culture sample from  
26 patients with a suspected BSI.

### 27 *Findings*

28 Nanopore mNGS confirmed all findings in patients with a positive blood culture (n=11), and identified  
29 pathogens relevant to the acute infection in an additional 11 patients with a negative blood culture.  
30 In an analysis of potential impact on the antibiotic treatment, we found that 59% (n=13) of mNGS  
31 positive answers could have impacted the treatment, with five cases of a change from ineffective to  
32 effective therapy.

### 33 *Interpretation*

34 This study demonstrates that culture-independent Nanopore mNGS directly on blood plasma could  
35 be a feasible alternative to blood culturing for infection diagnostics for patients admitted with a severe  
36 infection or sepsis. The method identified a relevant pathogen in patients with a broad range of  
37 etiologies including urinary tract infections and lower respiratory tract infections. With a turnaround  
38 time of 6 hours the method could provide unprecedented speed and sensitivity in BSI diagnostics.  
39  
40  
41

## 42 Introduction

43 Bloodstream infections (BSIs) are frequent and associated with a high mortality due to the  
44 development of sepsis.<sup>1</sup> The Global Burden of Disease study,<sup>2</sup> found that there were 50 million sepsis  
45 cases and 11 million sepsis related deaths in 2017, constituting nearly 20% of all global deaths. To  
46 treat sepsis, the current international guideline recommends that broad-spectrum empiric antibiotic  
47 treatment should be administered ideally within 1 hour from its recognition.<sup>3</sup> However, the empiric  
48 antibiotic treatment does not cover the causative pathogen in 20% of cases, and these patients have  
49 increased mortality (data from US and Canada).<sup>4,5</sup> To facilitate a targeted and effective antibiotic  
50 treatment to improve sepsis survival, an accurate and rapid identification of the causative pathogen  
51 and its antimicrobial susceptibility is crucial. However, gold-standard blood culturing fails to  
52 diagnose >50% of patients with clinical sepsis, possibly due to prior antibiotic treatment or a  
53 microbial load below the limit of detection.<sup>6</sup> Further, blood culturing has a turnaround time of 24-72  
54 hours, which contrasts the urgency to provide effective antibiotic treatment.<sup>7</sup> In addition to the  
55 urgency on a patient level, there is an increased focus on improving diagnostics to facilitate effective  
56 antimicrobial stewardship programs.<sup>8,9</sup>

57

58 This has prompted the development of novel approaches to BSI diagnostics including multiplex PCR  
59 assays, molecular target detection with magnetic resonance, and metagenomic next-generation  
60 sequencing (mNGS) of microbial cell-free DNA (cfDNA) in plasma.<sup>10-13</sup> Particularly mNGS has gained  
61 attention due to its high sensitivity and hypothesis-free approach. While cfDNA mNGS has an  
62 increased number of relevant detections of pathogens compared to the standard blood culturing, the  
63 method has generally been applied on DNA sequencing platforms with long turnaround times that  
64 compromise the urgency of diagnosing BSIs. We leveraged the real-time Nanopore sequencing  
65 platform to develop a plasma mNGS assay with a short turnaround time and evaluated it in a  
66 prospective observational study in an emergency ward setting against gold-standard blood culturing.

## 67 Methods

### 68 *Study design*

69 We performed a cross-sectional study in the emergency ward at Aalborg University Hospital, which is  
70 the largest hospital in the North Denmark Region with highly specialized functions and a total of 558  
71 beds (catchment population approximately 600,000 inhabitants). Patients were prospectively  
72 included upon suspicion of a BSI. All included patients provided written informed consent (see ethics  
73 section) and were included in the period from 1 June to 31 December 2022. For included patients, a  
74 blood sample (9mL K2EDTA) for mNGS was drawn from the same venipuncture as a blood culture for  
75 routine diagnostics. Following inclusion, patient metadata was collected from their electronic medical  
76 record, which included medical history and diagnosis, clinical microbiology results, biochemical blood  
77 parameters, and antimicrobial therapy. As a negative reference group, blood donor samples were  
78 collected from the blood bank at Aalborg University Hospital from 12 donors and handled in parallel  
79 with the clinical samples.

80

### 81 *Study population*

82 Study inclusion criteria comprised that the patient was admitted to the emergency ward at Aalborg  
83 University Hospital and admitted upon suspicion of a BSI as adjudicated by a requested blood culture.

84 Patients were excluded from the study if they were younger than 18 years old or were unable to  
85 provide written informed consent. Inclusion was conducted on selected weekdays from 8AM-4PM.

86

#### 87 *Patient subgrouping*

88 Based on the medical records, patients were subdivided into the following groups as adjudicated by a  
89 clinical microbiologist (KKS): patients with a positive blood culture (BSI-confirmed); patients with a  
90 negative blood culture but a high suspicion of a true BSI (BSI-suspected); patients with a negative  
91 blood culture and no suspicion of an infectious disease (BSI-absent); and patients with a negative  
92 blood culture and low to medium suspicion of a true BSI (BSI-unlikely). Patients were assigned based  
93 on all available microbiology test results (blood culture results, urine culture, respiratory samples etc.)  
94 combined with a clinical evaluation of the patients including vital signs (e.g. temperature, pulse, blood  
95 pressure, respiration rate), biochemical parameters (e.g. CRP, white blood cell count) and imaging (e.g.  
96 chest x-ray, CT abdomen and chest, endoscopies). Patients in groups BSI-confirmed, BSI-suspected,  
97 and BSI-absent were selected for analysis.

98

#### 99 *Clinical microbiology*

100 All clinical microbiology results were subsequently obtained from patient medical records (wwBakt,  
101 Autonik AB, Sweden) and no follow-up analyses were conducted. Clinical microbiology analyses were  
102 conducted at the Department of Clinical Microbiology at Aalborg University Hospital. A standard blood  
103 culture using two BD BACTEC™ Plus Aerobic medium and one BD BACTEC™ Lytic Anaerobic medium  
104 glass culture vials were obtained from a peripheral site upon submission and incubated in the BACTEC  
105 FX Top instrument (Becton Dickinson AB, Stockholm, Sweden). The identification of species was  
106 conducted with conventional biochemical tests and matrix-assisted laser desorption ionization–time  
107 of flight (MALDI Biotyper 3.1, Bruker Daltonics Microflex LT, MBT 6903 MSP Library).

108

#### 109 *Plasma preparation and DNA extraction*

110 Plasma was prepared from study blood samples by centrifugation at 1,600g at 4°C for 10 minutes  
111 within 1hr from blood draw at the Department of Biochemistry at Aalborg University Hospital. The  
112 plasma supernatant was subsequently centrifuged again at 16,000g at 4°C for 10 minutes and the new  
113 supernatant was obtained and stored at -80°C until analysis. At analysis, plasma samples were thawed,  
114 and single-stranded oligonucleotides were added at a known concentration to allow for absolute  
115 quantification of microbial DNA (unpublished). DNA was extracted from 2mL plasma using the QIAamp  
116 MinElute ccfDNA kit (Qiagen) standard protocol with DNA elution in 30µL. At least one process control  
117 was included in each batch, consisting of 2mL nuclease-free water (Qiagen). DNA was quantified with  
118 the Qubit dsDNA HS Assay Kit on a Qubit 4 Fluorometer (Thermo Fisher). DNA length was assessed  
119 with the D1000 High Sensitivity ScreenTape Assay on a TapeStation 4150 (Agilent).

120

#### 121 *Library preparation and sequencing*

122 10-18µL of extracted DNA was used as input to the SRSly™ DNA NGS Library Preparation PicoPlus Kit  
123 (Claret Biosciences) with custom primers. The library preparation was carried out according to the  
124 SRSly protocol for extreme short fragment retention. At least one process control was included in  
125 each batch, consisting of 18µL nuclease-free water (Qiagen). Subsequently, samples were prepared  
126 for Oxford Nanopore sequencing with the ligation kit (Oxford Nanopore Technologies, SQK-LSK114).  
127 Libraries were sequenced on a PromethION 24 on R10.4.1 flow cells and basecalled with the super-  
128 accurate model (Guppy 7.0.9) with a quality cut-off at a phred score of 10 applied.

## 129 *Data analysis and bioinformatics*

130 Basecalled reads were demultiplexed, trimmed for adapters, checked for any remaining barcodes or  
131 adapters with Cutadapt (version 4.4).<sup>14</sup> Reads with no alignments to the human genome (BLAST  
132 version 2.15.0) were aligned with Bowtie2 to a database consisting of Genome Taxonomy Database  
133 (GTDB) representative bacterial and archaeal genomes from release 207 and virus (complete  
134 genomes) and fungi (all genomes) from NCBI RefSeq release 215 as well as the reference NCBI Homo  
135 sapiens genome (T2T).<sup>15,16</sup> All identified microbial taxonomies were re-evaluated with proprietary  
136 refinement algorithms. Reads from the single-stranded spike-ins were used to quantify DNA for all  
137 identified pathogens in genome equivalents per microliter (GPM). The absolute load of microbial DNA  
138 in patient samples was compared to the 12 blood donor samples to establish thresholds for clinical  
139 relevance.

140

## 141 *Assessment of clinical relevance of mNGS results*

142 To evaluate the relevance of mNGS findings, results were contextualized with the patient's other  
143 microbiological results and overall clinical picture. mNGS results were grouped on a patient level based  
144 on the clinical relevance of identifications as adjudicated by two clinical microbiologists (KKS and  
145 HLN).<sup>12</sup> "Confirmed" was assigned only when at least one of the pathogens identified by mNGS was  
146 also identified by blood culture. "Probable" was assigned when at least one of the pathogens identified  
147 by mNGS was also identified in other samples from the suspected infection site or when the mNGS  
148 results aligned very well with the clinical picture (e.g. *Escherichia coli* identified in a patient with  
149 suspected urinary tract infection (UTI)). "Possible" was assigned when at least one of the pathogens  
150 identified by mNGS was consistent with the clinical picture. "Unlikely" was assigned when the  
151 pathogens identified by mNGS were considered irrelevant in the context of the acute infection.

152

## 153 *Potential clinical impact analysis*

154 To evaluate the potential impact on patient antibiotic treatment, the microbial identifications from  
155 mNGS were compared to results from routine diagnostics, medical record (suspected site of infection),  
156 and the antibiotics administered prior to and during the relevant admission by two clinical  
157 microbiologists (KKS and HLN). As the mNGS analysis was conducted in batches following completed  
158 patient inclusion, the impact analysis was based on the turnaround time in a potential real-time setup,  
159 which was estimated to be around 6 hours (Figure 2b). This aligns with previously reported turnaround  
160 times for Nanopore mNGS.<sup>17</sup>

161

## 162 *Statistical analysis*

163 Confidence intervals for sensitivity and specificity were calculated using the Clopper-Pearson exact  
164 method. If not specified otherwise, a two-sided Wilcoxon-Mann-Whitney test was used to compare  
165 distributions. In case of multiple comparisons, the p-values were adjusted with the Holm-Bonferoni  
166 method. All statistical analyses were conducted in R (version 4.2.0).

167

## 168 *Ethics*

169 The study protocol was reviewed and accepted by The Scientific Ethics Committee for the North  
170 Denmark Region (N-20220015). The study was also approved according to GDPR (article 30) regulation  
171 for the North Denmark Region (Project-ID: F2023-056).

172

173

174 *Role of the funding source*


175 The funders of the study had no role in study design, patient inclusion, data analysis, data  
176 interpretation, or writing of the manuscript.

177 **Results**

178 *Patient inclusion and sample selection*

179 During the study period, a total of 186 patients provided written informed consent. Of these, 181  
180 qualified for analysis, and 40 patients were selected after subdividing the patients into four groups:  
181 BSI-confirmed (n=11), BSI-suspected (n=25), BSI-absent (n=4), and BSI-unlikely (n=141) (Figure 1). Only  
182 samples from patients in BSI-confirmed, BSI-suspected, and BSI-absent were subjected to mNGS  
183 analysis.

184



185  
186 Figure 1. Flowchart of patient inclusion and selection for analysis.

187

188 *Patient characteristics*

189 A subset of 40 patients (50% female) with a median age of 71 years (interquartile range (IQR): 59-84)  
190 were analyzed with mNGS (Table 1). Urinary tract infection (UTI, n=12) and lower respiratory tract  
191 infection (LRI, n=10) were the most frequent types of infection among the patients. Of the 12 patients  
192 admitted with a UTI, six were suspected to have pyelonephritis (Table 2). More than half of the  
193 patients had one or more comorbidities, including diabetes (n=13), cancer (n=7), and chronic  
194 obstructive pulmonary disease (n=5). Emphasizing that our categorization of BSI was successful, we  
195 found that compared to BSI-absent (n=4, median: 1.3 mg/L) and BSI-unlikely (n=141, median: 67  
196 mg/L), the CRP level was significantly higher in patients from BSI-confirmed (n=11, median: 216 mg/L,  
197 p=0.047 and p=0.002, Wilcoxon-Mann-Whitney) and BSI-suspected (n=25, median: 204 mg/L, p=0.035  
198 and p<0.0001, Wilcoxon-Mann-Whitney) (appendix p 3).

199

	Patient subgroups		
	BSI-confirmed (N=11)	BSI-suspected (N=25)	BSI-absent (N=4)
<b>Patient demographics</b>			
Age (years)			
Median (IQR)	72 (68-5-81-5)	67 (59-84)	56.5 (50.5-67.5)
Range	24-92	23-93	46-87
Female, n (%)	3 (27)	15 (60)	2 (50)
<b>Comorbidities, n (%)</b>			
Any	4 (36)	15 (60)	3 (75)
Diabetes	3 (27)	9 (36)	1 (25)
Cancer	1 (9)	5 (20)	1 (25)
Chronic obstructive pulmonary disease	1 (9)	3 (12)	1 (25)
Alcoholism	1 (9)	1 (4)	1 (25)
Dialysis	0 (0)	0 (0)	0 (0)
<b>Immunosuppressive therapy<sup>a</sup>, n (%)</b>	0 (0)	2 (8)	0 (0)
<b>Clinical presentation, n (%)</b>			
Oral antibiotics at admission <sup>b</sup>	0 (0)	7 (28)	0 (0)
Sepsis according to qSOFA <sup>c</sup> criteria (≥2)	2 (18)	4 (16)	0 (0)
<b>Primary site of infection</b>			
Urinary tract infection	6 (55)	6 (24)	-
Respiratory tract infection	0 (0)	10 (40)	-
Skin and soft tissue infections	1 (9)	4 (16)	-
Diverticulitis	0 (0)	1 (4)	-
PICC-line	0 (0)	1 (4)	-
Idiopathic pancreatitis	1 (9)	0 (0)	-
Unknown	3 (27)	3 (12)	-
30-day all cause mortality	0 (0)	1 (4)	0 (0)

200 Table 1. Patient characteristics. <sup>a</sup>Immunosuppressive therapy covers ATC codes L04 and H02. <sup>b</sup>Oral  
 201 antibiotics administered at the general practitioner in relation to the relevant infection. <sup>c</sup>qSOFA, Quick  
 202 Sequential Organ Failure Assessment.<sup>18</sup>  
 203

204 *Clinical microbiology*

205 The 11 positive blood culture identifications from patients in the BSI-confirmed group comprised *E.*  
206 *coli* (n=7), *Staphylococcus epidermidis* (n=2), *Enterococcus faecalis* (n=1), and *Staphylococcus aureus*  
207 (n=1), reflecting that most patients in this group were admitted with a urinary tract focus. Of the 25  
208 patients in BSI-suspected, 14 patients (56%) had positive cultures from urine (n=10), sputum (n=2),  
209 bronchoalveolar lavage (n=1), or other sites (n=3), while the remaining patients had no positive  
210 microbiological tests to guide the antibiotic treatment. The pathogens identified in other cultures for  
211 patients in BSI-suspected were *E. coli* (n=7), *Pseudomonas aeruginosa* (n=2), and others (n=9) (Table  
212 2).

213

214 *Metagenomic DNA sequencing analysis*

215 From all 40 patients, plasma cfDNA was sequenced and patient samples had a mean read depth of  
216 10·1M reads (s.d. 5·6M) (appendix p 11). Patients in BSI-confirmed (n=11, median: 10·1 ng/mL) had  
217 significantly higher levels of cfDNA in plasma compared to blood donor samples (n=12, median: 2·3  
218 ng/mL) (p=0·00058, Wilcoxon-Mann-Whitney), which was also the case for patients in BSI-suspected  
219 (n=25, median: 14·3 ng/mL) (p<0·00001, Wilcoxon-Mann-Whitney) in accordance with previous  
220 reports (Figure 3d).<sup>19</sup>

221


222 mNGS confirmed all positive blood culture findings, and three patients in this group had 1 or 2  
223 additional pathogens identified (Table 2). The additional findings comprised two bacteria  
224 (*Enterococcus faecium* and *Citrobacter koseri*) and two viruses (human cytomegalovirus (human  
225 betaherpesvirus 5, CMV) and Kaposi's sarcoma-associated herpesvirus (human gammaherpesvirus 8,  
226 KSHV)). In the BSI-suspected group, 1-6 pathogens were identified in 12 of 25 patients. 11 of the 12  
227 patients with a positive mNGS result had one or more pathogens identified that was deemed relevant  
228 for the acute infection by a clinical microbiologist and assigned either 'Probable' (n=10) or 'Possible'  
229 (n=1) (Figure 3a). This included common pathogens like *E. coli*, *P. aeruginosa*, and *Streptococcus*  
230 *pneumoniae*, but also rarer pathogens like *Serratia spp.*, *Raoultella planticola*, and *Veillonella atypica*.  
231 The patient with a positive mNGS result, that was categorized as 'Unlikely' to be relevant to the acute  
232 infection had *Clostridioides difficile* identified. No pathogens were identified in the BSI-absent group.  
233 Evaluated against blood culture, the sensitivity was 100% (confidence interval 71·5-100·0%) and the  
234 specificity was 59% (confidence interval 38·9-76·5%) on a patient level (Clopper-Pearson exact  
235 method).

236

237 In five of the 12 patients with a pathogen identified by mNGS, another microbiological test result  
238 supported the finding (Table 2). All patients who received antibiotics prior to admission (n=7) were in  
239 the BSI-suspected group, of which three (p072, p105, and p140) were positive with mNGS.

240


241 With the single-stranded DNA spike-ins the load of pathogen DNA in plasma samples was quantified  
242 and pathogens were reported in titers from 0·5-321 genome equivalents per microliter (GPM), which  
243 is in accordance with previously reported pathogen DNA titers in BSIs.<sup>20</sup> Comparing the GPM of *E. coli*  
244 - the most frequently identified pathogen - across BSI-confirmed (n=7, median: 41·3 GPM) and BSI-  
245 suspected (n=6, median: 4·37 GPM), there was no significant difference (p=0·30, Wilcoxon-Mann-  
246 Whitney), which was also the case when comparing the total pathogen load in patients from BSI-  
247 confirmed (n=11, median: 41·3 GPM) and BSI-suspected (n=12, median: 4·71 GPM) with a positive  
248 mNGS test (p=0·10, Wilcoxon-Mann-Whitney) (Figure 3b).



249

250 Figure 2. a) Flowchart of the sample handling workflow for blood cultures and mNGS samples (created  
251 with biorender.com). b) A timeline for BSI diagnostics with Nanopore mNGS,<sup>17</sup> Illumina mNGS,<sup>13</sup> and  
252 blood culturing.<sup>7</sup>





253

254 Figure 3. a) Pie chart comparing blood culture and mNGS results. b) Total pathogen burden for patients

255 positive by mNGS in BSI-confirmed and BSI-suspected & compared only for *E. coli* where identified. c)

256 Number of pathogens identified with mNGS per sample. d) cfDNA concentrations across the different

257 patient groups and blood donor samples.

Patient group	Patient	Suspected primary site of infection	Blood culture results (positive bottles)	Other positive microbiology results Site: Species	mNGS result Species (GPM)
BSI-confirmed	p001	UTI	<i>E. faecalis</i> (3/3)	Urine: <i>E. faecalis</i>	<i>E. faecalis</i> (1)
	p002	UTI	<i>E. coli</i> (2/3)	Urine: <i>E. coli</i> Urine: <i>Enterococcus spp.</i>	<i>E. coli</i> (20-8)
	p020	UTI	<i>E. coli</i> (2/3)	Urine: <i>E. coli</i>	<i>E. coli</i> (1-6)
	p028	UTI	<i>E. coli</i> (3/3)	Urine: <i>E. coli</i>	<i>E. coli</i> (41-3)
	p098	Idiopathic pancreatitis	<i>E. coli</i> (3/3)		<i>E. coli</i> (0-9)
	p104	Infection w.o. focus	<i>S. epidermidis</i> (3/3)		<i>S. epidermidis</i> (52-4) KSHV <sup>a</sup> (1)
	p139	Infection w.o. focus	<i>E. coli</i> (3/3)		<i>E. coli</i> (102-2) <i>E. faecium</i> (0-7) CMV <sup>b</sup> (26-6)
	p141	Knee	<i>S. aureus</i> (3/3)	Urine: <i>S. aureus</i> Joint: <i>S. aureus</i>	<i>S. aureus</i> (31)
	p172	UTI (pyelonephritis)	<i>E. coli</i> (1/3)	Urine: <i>E. coli</i>	<i>E. coli</i> (59-4)
	p175	Infection w.o. focus	<i>S. epidermidis</i> (3/3)	Urine: <i>Enterococcus spp.</i>	<i>S. epidermidis</i> (53-8)
BSI-suspected	p183	UTI	<i>E. coli</i> (3/3)	Urine: <i>E. coli</i> Feces: <i>C. difficile</i>	<i>E. coli</i> (320-8) <i>C. koseri</i> (2-4)
	p012	Infection w.o. focus		Urine: <i>E. coli</i>	
	p018	PICC-line infection			
	p019	LRI			<i>E. coli</i> (58-7) <i>H. influenzae</i> (13-4) <i>Rothia dentocariosa</i> (4-5) <i>Streptococcus anginosus</i> (4-6) <i>Veillonella atypica</i> (6-5)
	p022	Infection w.o. focus			
	p027	Skin (erysipelas)			
	p047	LRI		Urine: <i>P. aeruginosa</i>	
	p049	LRI			<i>Proteus mirabilis</i> (0-5)
	p072	UTI			<i>E. coli</i> (2-8)
	p091	UTI (pyelonephritis)		Urine: <i>E. coli</i>	<i>E. coli</i> (1-8)
	p092	UTI (pyelonephritis)		Urine: <i>E. coli</i>	<i>E. coli</i> (0-9) <i>H. pylori</i> (13-8)
	p105	LRI		BAL: <i>P. aeruginosa</i>	<i>P. aeruginosa</i> (121-6)
	p106	LRI		Sputum: <i>S. pneumoniae</i> Sputum: <i>RS virus</i> <sup>c</sup>	
	p114	LRI			
	p127	Diverticulitis			<i>Raoultella planticola</i> (0-6)
	p128	LRI			<i>S. pneumoniae</i> (3-5)
	p136	Psoas		Abscess: <i>E. coli</i> Abscess: <i>C. albicans</i>	
	p140	UTI		Urine: <i>E. coli</i>	<i>E. coli</i> (5-9)
	p143	Decubitus os sacrum		Urine: <i>Enterococcus spp.</i> Wound: <i>Proteus spp.</i>	<i>C. difficile</i> (0-5)
	p146	Skin (erysipelas)		Wound: <i>S. aureus</i>	
p150	LRI				
p151	Infection w.o. focus				
p156	LRI		Urine: <i>K. pneumoniae</i>		
p162	LRI		Urine: <i>E. coli</i> Sputum: <i>H. influenzae</i>		
p164	UTI (pyelonephritis)		Urine: <i>E. coli</i>	<i>E. coli</i> (8)	
p173	UTI (pyelonephritis)		Urine: <i>Enterococcus spp.</i>	<i>Klebsiella spp.</i> <sup>d</sup> (5-8) <i>Acinetobacter bereziniae</i> (1) <i>Brevibacterium paucivorans</i> (2) <i>Leuconostoc pseudomesenteroides</i> (1-1) <i>Pantoea dispersa</i> (1-1) <i>Serratia spp.</i> <sup>d</sup> (3-1)	
BSI-absent	p016	-			
	p059	-			
	p068	-			
	p120	-		Skin: <i>S. aureus</i>	

258 Table 2. Results from conventional microbiological tests and mNGS. <sup>a</sup>KSHV: Kaposi's sarcoma-  
 259 associated herpesvirus; <sup>b</sup>CMV: Cytomegalovirus; <sup>c</sup>RS virus: Human respiratory syncytial virus; <sup>d</sup>Could  
 260 not be determined to species level with mNGS.  
 261

262 *Case series*

263 To contextualize the results of mNGS to the patient clinical presentation, we present a more detailed  
264 review of selected cases from BSI-confirmed and BSI-suspected groups, who were positive by mNGS.  
265 From the BSI-confirmed group three patients were selected for a more detailed analysis.

266

267 The first patient, p001, was admitted upon suspicion of a lower respiratory tract infection with a CRP  
268 of 109 mg/L (normal reference range <8 mg/L) and treated with empiric IV gentamicin+cefuroxime.  
269 During the admission the focus changed to a urinary tract infection with the finding of *E. faecalis* in  
270 blood and urine upon which the treatment was changed to ampicillin after 48hrs. mNGS also identified  
271 *E. faecalis* at 1 GPM.

272

273 The second patient, p104, with known Kaposi's sarcoma was admitted with acute abdominal pain with  
274 a CRP of 41 mg/L and no obvious origin of infection. Treatment was initiated with IV  
275 piperacillin+tazobactam and oral ciprofloxacin. 68 hours after admission a blood culture was positive  
276 for *S. epidermidis* with the patient's peripherally inserted central catheter (PICC) line as the suspected  
277 origin. This led to a change in treatment to vancomycin and a change of the PICC-line. mNGS identified  
278 *S. epidermidis* (52.4 GPM) and Kaposi's sarcoma-associated herpesvirus (KSHV) (1 GPM).

279

280 The third patient, p139, was admitted with infection without focus and elevated CRP of 248 mg/L. The  
281 patient had a kidney transplant and received immunosuppressives. *E. coli* was cultured from blood,  
282 and this was also identified by mNGS at 102 GPM. Additionally, mNGS identified *Enterococcus faecium*  
283 (0.7 GPM) and CMV (26.6 GPM). At day 11 of the hospitalization, a quantitative PCR for CMV was  
284 positive with 290 copies/mL.

285

286 From the BSI-suspected group three patients were selected for a more detailed description.

287

288 The first patient, p128, was admitted upon suspicion of pneumonia with CRP of 470 mg/L and a low  
289 systolic blood pressure of 99 mmHg. The patient was known with chronic obstructive pulmonary  
290 disease (COPD) and autoimmune hepatitis. The patient was seen by a general practitioner prior to the  
291 admission concerning the LRI, but it was unclear from the medical record if the patient was treated  
292 with antibiotics at admission. All microbiology tests conducted (blood culture, urine culture, *S.*  
293 *pneumoniae* urine antigen) were negative, while *S. pneumoniae* was identified by mNGS at 3.5 GPM.  
294 The patient was administered IV benzylpenicillin at admission with a good clinical response.

295

296 The second patient, p173, was admitted upon suspicion of a urinary tract infection and pyelonephritis  
297 with a CRP of 164 mg/L. The patient had a positive urine culture with *Enterococcus spp.* as the only  
298 positive microbiology result. The mNGS test was positive for several pathogens of which *Klebsiella spp.*  
299 were in the highest titer at 5.8 GPM. Three weeks prior to the relevant admission, *K. pneumoniae* was  
300 cultured from both blood and urine, suggesting that the mNGS result was relevant.

301

302 The third patient, p072, was admitted upon suspicion of a urinary tract infection and pyelonephritis  
303 with no positive microbiological tests (blood and urine cultures) during the same admission, while  
304 mNGS was positive for *E. coli* (2.8 GPM). At admission the patient was already receiving pivmecillinam  
305 ordinated from a general practitioner.

306

307 *Potential clinical impact*

308 The mNGS answers for the 22 patients where the result was either confirmed by blood culture or  
309 deemed relevant by a clinical microbiologist, were analyzed for potential clinical impact. In a real-time  
310 setting, the mNGS result could have affected the antimicrobial treatment in 13 cases (59%)  
311 subgrouping to 5 changes from ineffective to effective treatment, 7 escalations from oral to IV, and 1  
312 addition of an extra antimicrobial (more details in appendix p 8). The 5 cases where a change from  
313 ineffective to effective treatment could have been facilitated are particularly interesting, and in  
314 patients from BSI-confirmed this was achieved by identifying an unsuspected pathogen more rapidly  
315 than the blood culture (n=4), while it in patients from BSI-suspected was achieved by identifying an  
316 unsuspected pathogen not detected by blood culture (n=1).

317 **Discussion**

318 In recent years, multiple studies have assessed the use of cfDNA mNGS for BSI diagnostics on patients  
319 admitted to e.g. the intensive care unit,<sup>13,21</sup> the emergency ward,<sup>12</sup> hematology,<sup>22</sup> and pediatric  
320 departments.<sup>23</sup> In this study, we show that rapid Nanopore mNGS could be a feasible alternative to  
321 blood culturing, as the test confirmed all positive blood cultures (n=11) and provided a relevant  
322 pathogen identification in an additional 11 patients. In general, for patients admitted to the  
323 emergency ward, no or few microbiological results (e.g. from primary care or previous admissions) are  
324 available to guide the upfront antibiotic therapy, and rapid and sensitive infection diagnostics are most  
325 welcomed by treating physicians to provide effective antimicrobial therapy for the benefit of the  
326 patient and to use narrow-spectrum antibiotics to combat antimicrobial resistance development.<sup>24,25</sup>

327

328 The mNGS results reported in this study constitute both common and rare pathogens from various  
329 suspected body site origins including UTIs, LRIs, and intraabdominal abscesses, demonstrating  
330 applicability across a broad range of etiologies. To the best of our knowledge only a single study with  
331 four patients has evaluated the use of Nanopore sequencing for mNGS BSI diagnostics.<sup>26</sup> Our study  
332 establishes the feasibility of using the platform to decrease the turnaround time. We also introduce a  
333 quantitative measure of microbial cfDNA in the original sample as a way of standardizing results  
334 between patients (and possibly cohorts) and to allow for an improved clinical interpretation of results.

335

336 Validation and interpretation of mNGS results in patients with a negative blood culture is difficult and  
337 the many additional findings have led to questions on the clinical relevance of these identifications.<sup>27,28</sup>

338 In the BSI-suspected group from this study, the high number of microbiological tests from other sites  
339 that confirm the mNGS result and the fact that patients were included in this group upon suspicion of  
340 a systemic infection, supports the relevance of mNGS pathogen identifications. Further, no microbes  
341 were identified with mNGS in patients from the BSI-absent group. In addition to the finding of common  
342 pathogens, mNGS also identified microbes that were unlikely to be responsible for the acute infection.  
343 This includes *H. pylori*, CMV, KSHV, and *C. difficile*, and such findings necessitate that results are  
344 interpreted with caution.

345

346 We also demonstrate that a fast and sensitive mNGS test has the potential to impact a major fraction  
347 of antibiotic treatments. While mNGS tests for clinical microbiology diagnostics are expensive to  
348 conduct (the commercially available Karius test is priced at \$2000 per sample) the added value of  
349 increased sensitivity and fast turnaround time with Nanopore sequencing on antibiotic treatment may

350 impact mortality and length-of-stay to justify this increased cost.<sup>29</sup> More studies, and randomized  
351 interventional studies, are required to answer these questions. We see this test best applied to  
352 vulnerable patient groups where etiology determination is crucial for patient survival.

353

354 This study has several limitations. Firstly, only patients who could provide informed consent were  
355 included and the patients who were in septic shock were thus excluded. Secondly, the study was  
356 conducted in a non-real-time setup with batching of samples for analysis after all patients were  
357 included in the cohort. Finally, the setup of the study did not allow us to conduct follow-up  
358 microbiological tests to investigate mNGS findings.

359

360 In summary, this study provides a proof-of-concept for the use of Nanopore cfDNA metagenomics as  
361 a diagnostic tool for patients with a BSI. We showed that Nanopore mNGS is capable of identifying a  
362 pathogen relevant to the acute infection in twice the number of patients as gold-standard blood  
363 culturing, and that the method works on patients with a broad range of etiologies.

#### 364 **Declaration of interests**

365 MEN, SMK, HLN, and MA are in the process of filing patents related to algorithms presented in this  
366 study. MEN has stocks in Oxford Nanopore Technologies plc.

#### 367 **Data sharing**

368 Individual patient metadata is shared in the appendix. Microbial DNA sequencing data from positive  
369 mNGS tests is deposited in NCBI SRA and is accessible with the BioProject identifier PRJNA1108520.  
370 On reasonable request study protocol and informed consent form, will be shared from the publication  
371 date and onwards by contacting the corresponding author (ma@bio.aau.dk).

#### 372 **Acknowledgements**

373 The authors would like to thank Kia Brøchner Hjortshøj and Emilia Maria Eriksen Villholth for their  
374 efforts to include patients to the study. This research was funded by the Independent Research Fund  
375 Denmark (Grant no. 2096-00079B).

#### 376 **Funding**

377 The study was funded by a research grant from the Independent Research Fund Denmark (Grant no.  
378 2096-00079B).

379

## 380 References

- 381 1. Seymour CW, Gesten F, Prescott HC, Friedrich ME, Iwashyna TJ, Phillips GS, et al. Time to  
382 Treatment and Mortality during Mandated Emergency Care for Sepsis. *N Engl J Med*. 2017 Jun  
383 8;376(23):2235–44.
- 384 2. Rudd KE, Johnson SC, Agesa KM, Shackelford KA, Tsoi D, Kievlan DR, et al. Global, regional, and  
385 national sepsis incidence and mortality, 1990–2017: analysis for the Global Burden of Disease  
386 Study. *Lancet*. 2020 Jan 18;395(10219):200–11.
- 387 3. Evans L, Rhodes A, Alhazzani W, Antonelli M, Coopersmith CM, French C, et al. Surviving Sepsis  
388 Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021. *Crit Care*  
389 *Med*. 2021 Nov 1;49(11):e1063–143.
- 390 4. Kadri SS, Lai YL, Warner S, Strich JR, Babiker A, Ricotta EE, et al. Inappropriate empirical antibiotic  
391 therapy for bloodstream infections based on discordant in-vitro susceptibilities: a retrospective  
392 cohort analysis of prevalence, predictors, and mortality risk in US hospitals. *Lancet Infect Dis*.  
393 2021 Feb;21(2):241–51.
- 394 5. Kumar A, Ellis P, Arabi Y, Roberts D, Light B, Parrillo JE, et al. Initiation of inappropriate  
395 antimicrobial therapy results in a fivefold reduction of survival in human septic shock. *Chest*.  
396 2009;136(5):1237–48.
- 397 6. Yang L, Lin Y, Wang J, Song J, Wei B, Zhang X, et al. Comparison of Clinical Characteristics and  
398 Outcomes Between Positive and Negative Blood Culture Septic Patients: A Retrospective Cohort  
399 Study. *Infect Drug Resist*. 2021 Oct;14:4191–205.
- 400 7. Tabak YP, Vankeepuram L, Ye G, Jeffers K, Gupta V, Murray PR. Blood Culture Turnaround Time  
401 in U.S. Acute Care Hospitals and Implications for Laboratory Process Optimization. Carroll KC,  
402 editor. *J Clin Microbiol* [Internet]. 2018 Dec;56(12). Available from:  
403 <https://journals.asm.org/doi/10.1128/JCM.00500-18>
- 404 8. Nutman A, Tellapragada C, Giske CG, Yahav D. New evidence for managing Gram-negative  
405 bloodstream infections. *Curr Opin Infect Dis*. 2021 Dec 1;34(6):599–610.
- 406 9. Ku TSN, Al Mohajer M, Newton JA, Wilson MH, Monsees E, Hayden MK, et al. Improving  
407 antimicrobial use through better diagnosis: The relationship between diagnostic stewardship and  
408 antimicrobial stewardship. *Infect Control Hosp Epidemiol*. 2023 Dec;44(12):1901–8.
- 409 10. Seitz T, Holbik J, Hind J, Gibas G, Karolyi M, Pawelka E, et al. Rapid Detection of Bacterial and  
410 Fungal Pathogens Using the T2MR versus Blood Culture in Patients with Severe COVID-19.  
411 *Microbiol Spectr*. 2022 Jun 29;10(3):e0014022.
- 412 11. Zboromyrska Y, Cillóniz C, Cobos-Trigueros N, Almela M, Hurtado JC, Vergara A, et al. Evaluation  
413 of the Magicplex™ Sepsis Real-Time Test for the Rapid Diagnosis of Bloodstream Infections in  
414 Adults. *Front Cell Infect Microbiol*. 2019 Mar 12;9:56.
- 415 12. Blauwkamp TA, Thair S, Rosen MJ, Blair L, Lindner MS, Vilfan ID, et al. Analytical and clinical  
416 validation of a microbial cell-free DNA sequencing test for infectious disease. *Nature*  
417 *Microbiology*. 2019;4(4):663–74.
- 418 13. Grumaz S, Stevens P, Grumaz C, Decker SO, Weigand MA, Hofer S, et al. Next-generation  
419 sequencing diagnostics of bacteremia in septic patients. *Genome Med*. 2016;8(1):1–13.

- 420 14. Martin M. Cutadapt removes adapter sequences from high-throughput sequencing reads.  
421 EMBnet.journal. 2011 May 2;17(1):10–2.
- 422 15. Camacho C, Coulouris G, Avagyan V, Ma N, Papadopoulos J, Bealer K, et al. BLAST+: architecture  
423 and applications. BMC Bioinformatics. 2009 Dec 15;10:421.
- 424 16. Langmead B, Salzberg SL. Fast gapped-read alignment with Bowtie 2. Nat Methods.  
425 2012;9(4):357–9.
- 426 17. Gu W, Deng X, Lee M, Sucu YD, Arevalo S, Stryke D, et al. Rapid pathogen detection by  
427 metagenomic next-generation sequencing of infected body fluids. Nat Med. 2021;27(1):115–24.
- 428 18. Lambden S, Laterre PF, Levy MM, Francois B. The SOFA score-development, utility and challenges  
429 of accurate assessment in clinical trials. Crit Care. 2019 Nov 27;23(1):374.
- 430 19. Rhodes A, Wort SJ, Thomas H, Collinson P, Bennett ED. Plasma DNA concentration as a predictor  
431 of mortality and sepsis in critically ill patients. Crit Care. 2006;10(2):R60.
- 432 20. Bacconi A, Richmond GS, Baroldi MA, Laffler TG, Blyn LB, Carolan HE, et al. Improved sensitivity  
433 for molecular detection of bacterial and Candida infections in blood. J Clin Microbiol. 2014  
434 Sep;52(9):3164–74.
- 435 21. Kalantar KL, Neyton L, Abdelghany M, Mick E, Jauregui A, Caldera S, et al. Integrated host-microbe  
436 plasma metagenomics for sepsis diagnosis in a prospective cohort of critically ill adults. Nat  
437 Microbiol. 2022 Nov;7(11):1805–16.
- 438 22. Feng S, Rao G, Wei X, Fu R, Hou M, Song Y, et al. Clinical metagenomic sequencing of plasma  
439 microbial cell-free DNA for febrile neutropenia in patients with acute leukaemia. Clin Microbiol  
440 Infect. 2024 Jan;30(1):107–13.
- 441 23. Goggin KP, Gonzalez-Pena V, Inaba Y, Allison KJ, Hong DK, Ahmed AA, et al. Evaluation of Plasma  
442 Microbial Cell-Free DNA Sequencing to Predict Bloodstream Infection in Pediatric Patients with  
443 Relapsed or Refractory Cancer. JAMA Oncology. 2020;6(4):552–6.
- 444 24. Eubank TA, Long SW, Perez KK. Role of Rapid Diagnostics in Diagnosis and Management of  
445 Patients With Sepsis. J Infect Dis. 2020 Jul 21;222(Suppl 2):S103–9.
- 446 25. Al Jalbout N, Troncoso R Jr, Evans JD, Rothman RE, Hinson JS. Biomarkers and Molecular  
447 Diagnostics for Early Detection and Targeted Management of Sepsis and Septic Shock in the  
448 Emergency Department. J Appl Lab Med. 2019 Jan;3(4):724–9.
- 449 26. Grumaz C, Hoffmann A, Vainshtein Y, Kopp M, Grumaz S, Stevens P, et al. Rapid Next-Generation  
450 Sequencing–Based Diagnostics of Bacteremia in Septic Patients. J Mol Diagn. 2020;22(3):405–18.
- 451 27. Han D, Li R, Shi J, Tan P, Zhang R, Li J. Liquid biopsy for infectious diseases: A focus on microbial  
452 cell-free DNA sequencing. Theranostics. 2020;10(12):5501–13.
- 453 28. Pietrzak B, Kawacka I, Olejnik-Schmidt A, Schmidt M. Circulating Microbial Cell-Free DNA in Health  
454 and Disease. Int J Mol Sci [Internet]. 2023 Feb 3;24(3). Available from:  
455 <http://dx.doi.org/10.3390/ijms24033051>
- 456 29. O’Grady J. A powerful, non-invasive test to rule out infection. Nature Microbiology.  
457 2019;4(4):554–5.